Clinical Trial Update: A Study on the Tolerability and Early Efficacy of hLF1-11 in Patients With Bacteremia Due to S. Epidermidis [Phase 1, Phase 2]

View source ↗

Summary

The trial evaluating tolerability and early efficacy of the hLF1-11 peptide in bacteremia due to Staphylococcus epidermidis has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bacteremia
• Staphylococcal Infections

Drugs mentioned

• hLF1-11 (hLF1-11)

Snippet

Sponsor: AM-Pharma | Conditions: Staphylococcal Infections, Bacteremia | Phase 1, Phase 2 | Status: WITHDRAWN